Novartis India Stock Soars 20% on ₹1,446 Crore Stake Sale

Introduction

Shares of Novartis India Limited surged by as much as 20% on Friday, February 20, 2026, hitting their upper circuit limit. The dramatic rise followed an announcement from its Swiss parent company, Novartis AG, that it had agreed to sell its entire 70.68% stake in the Indian-listed entity. The transaction, valued at approximately ₹1,446 crore, will transfer control to a consortium of private equity investors, marking a significant shift in the company's ownership structure.

The Landmark Transaction

Novartis AG entered into a share purchase agreement to divest its controlling stake, which consists of 1,74,50,680 equity shares. The buyer is a consortium led by WaveRise Investments Limited, ChrysCapital Fund X, and Two Infinity Partners. The deal was signed at a price of ₹860.64 per share, representing a 3.64% premium over the stock's closing price of ₹830.45 on the previous day. This transaction is part of a broader strategic review initiated by Novartis AG in February 2024, aimed at transforming the global firm into a pure-play innovative medicines company.

Mandatory Open Offer for Public Shareholders

The acquisition of a controlling stake has triggered a mandatory open offer under Indian takeover regulations. The consortium has announced an offer to acquire up to an additional 26% of Novartis India's voting share capital from public shareholders. This offer allows minority investors to tender up to 64,19,608 equity shares at the same price of ₹860.64 per share. If fully subscribed, the total consideration for the open offer would amount to ₹552.49 crore, payable entirely in cash.

Market Reaction and Stock Performance

The market responded with strong optimism to the news. Novartis India's stock price rallied sharply, reaching an intra-day high of ₹979.95 before hitting the 20% upper circuit at ₹996.50 on the BSE. The trading volume was significantly higher than average, reflecting keen investor interest. Despite this surge, the stock remains below its 52-week high of ₹1,099.90, recorded in May 2025. Over the past year, the stock has delivered a return of over 14%, while its five-year return stands at 56%.

Key Deal Metrics

Change in Control and Future Structure

Upon completion of the transaction, Novartis AG will cease to be the promoter of Novartis India and will hold no shares. The ChrysCapital-led consortium will assume control and be classified as the new promoter. If the open offer is fully subscribed, the consortium's combined shareholding will increase to 96.68%. The acquirers have clarified their intention to keep Novartis India listed on the stock exchanges and will take necessary steps to comply with the minimum 25% public shareholding requirement if needed. As part of the agreement, Novartis India will change its name to remove any reference to the seller group within 120 days of the deal's closing.

Strategic Rationale for Novartis AG

The divestment aligns with Novartis AG's global strategy to streamline its operations and focus on its core business of innovative medicines. The strategic review of the Indian-listed arm, which began two years ago, concluded with this decision to exit. This move allows the parent company to reallocate capital and resources toward its primary growth areas, particularly in Cardio-Renal Metabolic and Oncology portfolios.

Novartis's Continued Commitment to India

It is important to note that Novartis AG is not completely exiting the Indian market. The company will maintain a significant presence through its wholly-owned subsidiary, Novartis Healthcare Private Limited (NHPL). This separate, unlisted entity houses the commercial arm for Novartis's innovative medicines, the Novartis Corporate Center in Hyderabad, and extensive R&D operations, including clinical trials at over 300 sites across the country. NHPL employs more than 9,000 associates in India and will continue to be central to Novartis's strategy in the region.

Conclusion

The sale of Novartis AG's stake in its Indian-listed unit represents a major turning point for Novartis India, transitioning its ownership from a global pharmaceutical giant to a private equity-backed entity. The deal provides clarity on the company's future and has been well-received by the market. The transaction is subject to customary closing conditions and is expected to be completed in the third quarter of 2026, pending regulatory approvals.